When the U.S. government approves a vaccine, the clinical trial process does not stop. The fourth type of clinical evaluation is called Phase 4 or Post-Market Survalence.
These studies aggregate real-world evidence that hopefully meets or extends results reported in the pre-approval clinical trial.